Eli Lilly (LLY) shares surged 4.84% to close at $1058.39 following a clinical setback for competitor Novo Nordisk and the official launch of the Zepbound KwikPen.
- Novo Nordisk’s REDEFINE 4 trial failed to meet non-inferiority benchmarks against Lilly’s portfolio, reinforcing investor confidence in its market dominance.
- The Zepbound KwikPen, a multi-dose delivery device, is now officially available through LillyDirect to simplify administration for patients.
- This new delivery option starts at a price of $299 monthly, specifically targeting the self-pay patient segment.